Mumbai, Sept. 17 -- Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD) and Gastric Ulcer. Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in APD management.

Tegoprazan is already approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the United States.

M.V. Ramana, chief executive officer, branded markets (India and emerging markets), Dr. Reddy's, said:...